The Cooper Companies, Inc. (BMV:COO)
Mexico
· Delayed Price · Currency is MXN | Market Cap | 218.19B |
| Revenue (ttm) | 72.00B |
| Net Income (ttm) | 6.96B |
| Shares Out | n/a |
| EPS (ttm) | 34.81 |
| PE Ratio | 31.35 |
| Forward PE | 13.66 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 57 |
| Average Volume | 490 |
| Open | 1,221.00 |
| Previous Close | 1,242.72 |
| Day's Range | 1,221.00 - 1,221.00 |
| 52-Week Range | 1,221.00 - 1,600.13 |
| Beta | 1.07 |
| RSI | 36.00 |
| Earnings Date | Jun 4, 2026 |
About The Cooper Companies
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women’s health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cor... [Read more]
Financial Performance
In fiscal year 2025, The Cooper Companies's revenue was $4.09 billion, an increase of 5.06% compared to the previous year's $3.90 billion. Earnings were $374.90 million, a decrease of -4.44%.
Financial numbers in USDNews
CooperVision Launches MADE BETTER™ Promise Beginning with MyDay® Contact Lenses*¹
New sustainability platform reflects company's commitment to responsible sourcing, moreefficient manufacturing, and offsetting a portion of plastic footprint *†1 ROCHESTER, N.Y., April 9, 2026 /PRNews...
The Cooper Companies Earnings Call Transcript: Q1 2026
Q1 2026 saw strong revenue and earnings growth, driven by product launches, operational efficiencies, and robust cash flow. Guidance for earnings and free cash flow was raised, with continued momentum expected in the Americas and EMEA, while Asia Pac is set to recover in the second half.
CooperCompanies Announces First Quarter 2026 Results
SAN RAMON, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended Janua...
CooperCompanies Announces Release Date for First Quarter 2026
SAN RAMON, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will report first quarter 2026 financial results on Thursday, M...
The Cooper Companies Transcript: 44th Annual J.P. Morgan Healthcare Conference
Operating in growing contact lens and fertility markets, the company is focused on organic growth, product innovation, and capital efficiency. Strategic review is underway to assess business structure, with strong free cash flow and market share gains expected.
'Forgotten' stocks that could be 2026 powerhouses
Boyar Research is out with its "Forgotten Forty" list, comprising 40 overlooked stocks that are most likely to outperform this year. Boyar Research president, Jonathan Boyar, joins Market Catalysts ho...
CooperCompanies to Present at the J.P. Morgan Healthcare Conference
SAN RAMON, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will participate at the J.P. Morgan Healthcare Conference on We...
CooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Directors
SAN RAMON, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today that the Company's Board of Directors (the “Board”) has appointed ...
Cooper Companies Launches Portfolio Review To 'Unlock Value'
Cooper Companies (NASDAQ: COO) stock rose Friday after the company reported better-than-expected fourth-quarter earnings and upbeat financial guidance.
The Cooper Companies Earnings Call Transcript: Q4 2025
Q4 revenue hit a record $1.065B, up 4.6% year-over-year, with strong MyDay and MiSight growth offsetting softness in China. Fiscal 2026 guidance calls for 4.5–5.5% organic growth and $575–$625M free cash flow, with continued focus on share repurchases and a formal strategic review underway.
Cooper Companies initiates strategic review; shares jump
Medical device maker Cooper Companies said it is initiating a formal strategic review aimed at identifying opportunities to enhance long-term shareholder value, sending shares up 11.7% in extended tra...
CooperCompanies Announces New Chair of the Board and Strategic Review
SAN RAMON, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today that its Board of Directors has appointed Colleen Jay to succeed c...
CooperCompanies Announces Fourth Quarter and Full Year 2025 Results
SAN RAMON, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today financial results for its fiscal fourth quarter and full ye...
Cooper Companies Likely To Report Higher Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
The Cooper Companies, Inc. (NASDAQ: COO) will release earnings results for the fourth quarter after the closing bell on Thursday, Dec. 4.
Browning West Delivers Letter to The Cooper Companies Board of Directors
Cooper's Lack of Strategic Focus, Misaligned Incentives, and Inadequate Board Oversight Have Led to Meaningful Underperformance
Jana Partners push to break up Cooper Cos. could change the stock's outlook
Jana announced a top portfolio position in Cooper and plans to push for strategic alternatives, including a potential combination for its contact lens unit.
CooperCompanies Announces Release Date for Fourth Quarter and Full Year 2025
SAN RAMON, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will report fourth quarter and full year 2025 financial results...
Overlooked Stock: Activist Investor Taps COO Amid 30% Y/Y Slide
Shares of Cooper Companies (COO) rallied on Monday's session as an activist investor eyes a turnaround. Reports say Jana Partners is pushing for the company to merge with Bausch + Lomb (BLCO) among ot...
Activist investor Jana Partners takes stake in medical device maker Cooper Companies, WSJ says
The hedge fund will push Cooper to improve how it allocates capital in order to boost returns, the WSJ said.
Activist Jana Takes Stake in Cooper, a Maker of Medical Devices
Bausch + Lomb is seen as a potential buyer for the contact-lens unit and the CEO said he would be interested.
CooperCompanies Announces Expanded Share Repurchase Program
SAN RAMON, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today its Board of Directors has approved a $1 billion increase ...
The Cooper Companies Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
Organic growth lagged due to clariti inventory drawdown and China e-commerce headwinds, but MyDay and MiSight products are driving recovery. Market share is expected to rebound as MyDay supply improves and private label deals expand. Free cash flow and profitability are set to rise, with a focus on efficiency and shareholder returns.
Stock Of The Day: Time To Buy Cooper Companies?
Cooper Companies, Inc. COO is trading higher on Friday. There is a chance that the stock goes into a new uptrend.
Cooper Companies Posts Downbeat Sales, Joins NetApp, Urban Outfitters, Nvidia And Other Big Stocks Moving Lower In Thursday Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Thursday.
The Cooper Companies Earnings Call Transcript: Q3 2025
Q3 saw 5.7% revenue growth and strong margins, led by MyDay lens momentum and robust free cash flow, though clariti and Asia-Pacific e-commerce softness weighed on results. Guidance calls for 2%-4% organic growth in Q4, with new MyDay contracts and efficiency initiatives expected to drive 2026 gains.